On April 2, 2024 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported its financial results for the full year 2023 and provided a business update (Press release, AIM ImmunoTech, APR 2, 2024, View Source [SID1234641688]). As previously announced, the Company will host a conference call and webcast today, Tuesday, April 2, 2024, at 8:30 AM ET (details below).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"AIM reported positive data across many fronts in 2023 and the first quarter of 2024. We intend to build on this momentum throughout the year, as we focus on the execution of our operational, clinical and regulatory initiatives. My goal is to create stockholder value in the near- and long-term as positive data continues to come in," commented AIM Chief Executive Officer Thomas K. Equels.
Recent Highlights
Announced in March 2024 the publication of positive findings from Early Access Program evaluating Ampligen in the treatment of pancreatic cancer in the prestigious journal Clinical Cancer Research
AMP-518 Clinical Study: Phase 2 study evaluating Ampligen as a potential therapeutic for people with the Post-COVID condition of fatigue
Last subject treated and study completed in November 2023
Reported positive topline results in February 2024, offering preliminary evidence that Ampligen may reduce fatigue in subjects with Post-COVID conditions
Bolstered intellectual property estate with November 2023 issuance of key U.S. patent for Ampligen in combination with an anti-PD-L1 antibody – such as AstraZeneca’s Imfinzi (durvalumab) – for the treatment of cancer
DURIPANC Clinical Study: Phase 1b/2 clinical trial combining AIM’s Ampligen with Imfinzi for the treatment of pancreatic cancer
Opened for enrollment and enrolled first subject in January 2024 at Erasmus Medical Center ("Erasmus MC")
First subject dosed in February 2024 at Erasmus MC
Expected Upcoming Pipeline Milestones
Q2 2024
Post-COVID Conditions (AMP-518) – Final dataset
Advanced Recurrent Ovarian Cancer – Protocol-planned interim results
2024
Locally Advanced Pancreatic Adenocarcinoma (AMP-270) – First subject dosed
Publications of data in scientific journals
Summary of Financial Highlights for Fiscal Year 2023
As of December 31, 2023, AIM reported cash, cash equivalents and marketable investments of $13.1 million, compared to $34.2 million as of December 31, 2022.
Research and development expenses for the year ended December 31, 2023, were $10.9 million, compared to $7.0 million for the year ended December 31, 2022.
General and administrative expenses for the year ended December 31, 2023, were $21.1 million, compared to $13.1 million for the year ended December 31, 2022.
Please refer to the full 10-K for complete details.
Conference Call and Webcast Details
As previously announced, the Company will host a quarterly conference call and webcast to discuss the operational and financial results today, April 2, 2024, at 8:30 AM ET.
The call will be hosted by members of AIM’s leadership team, Thomas K. Equels, Chief Executive Officer and Christopher McAleer, PhD, Scientific Officer. Interested participants and investors may access the conference call by dialing (877) 407-9219 (domestic) or (201) 689-8852 (international) and referencing the AIM ImmunoTech Conference Call. The webcast will be accessible on the Events page of the Investors section of the Company’s website, aimimmuno.com, and will be archived for 90 days following the live event.